{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:16:02Z","timestamp":1775571362951,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the S&T Program of Xiongan New Area","award":["XA202401102004K"],"award-info":[{"award-number":["XA202401102004K"]}]},{"name":"S&T Program of Hebei","award":["244X7701D"],"award-info":[{"award-number":["244X7701D"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["SHOUFA 2022-2-2016"],"award-info":[{"award-number":["SHOUFA 2022-2-2016"]}]},{"name":"National Key Research and Development Program of China","award":["2020YFC2005403"],"award-info":[{"award-number":["2020YFC2005403"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bloodstream infection (BSI) is associated with a high mortality, ranging from 17 to 32%. Once pathogens enter the bloodstream, they can activate platelets and trigger systemic inflammation. Antiplatelet agents suppress platelet activation and modulate inflammatory responses; however, it remains unclear whether their use reduces mortality in patients with BSI. This study aimed to evaluate the impact of antiplatelet therapy on clinical outcomes in patients with BSI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients diagnosed with BSI at Xuanwu Hospital, Capital Medical University, between 2013 and 2023. Patients were categorized into antiplatelet and non-antiplatelet groups. Propensity score matching was performed to minimize potential confounders, including age, sex, body mass index, year of onset, Charlson Comorbidity Index, and anticoagulant therapy. For the primary outcome (30-day all-cause mortality), group differences were analyzed using the logistic regression models, with results reported as odds ratios and 95% confidence intervals. Secondary endpoints, including respiratory failure, septic shock, acute kidney injury, and bleeding events, were similarly compared using the logistic regression. Subgroup analyses were performed according to causative pathogens and types of antiplatelet agents, with covariates showing standardized mean differences &gt;0.1 included in the models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main results<\/jats:title>\n                    <jats:p>\n                      After Propensity score matching, a total of 248 patients were included in the analysis, with 124 patients in each group). The 30-day all-cause mortality following BSI diagnosis was significantly lower in the antiplatelet group (OR 0.35; 95% CI 0.17\u20130.71,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004). Septic shock, respiratory failure, acute kidney injury, and bleeding events showed no significant differences between groups (OR 1.08; 95% CI 0.50\u20132.34;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.843, OR 0.72; 95% CI 0.33\u20131.60;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.424, OR 1.20; 95% CI 0.31\u20132.33;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.608, OR 0.71; 95% CI 0.55\u20132.37;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.712). Subgroup analyses revealed that antiplatelet therapy significantly reduced mortality in patients with Gram-negative BSI (OR 0.26; 95% CI 0.08\u20130.87;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.029). In addition, clopidogrel monotherapy was associated with lower mortality (OR 0.17; 95% CI 0.03\u20130.90;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.017).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with BSI, antiplatelet therapy significantly reduced 30-day all-cause mortality without an increasing risk of bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-026-04103-7","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T03:15:12Z","timestamp":1772421312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiplatelet therapy is associated with reduced mortality in patients with bloodstream infection: a propensity score-matched cohort study"],"prefix":"10.1186","volume":"31","author":[{"given":"Sijing","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lipo","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojie","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yachan","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"11","key":"4103_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2404991","volume":"392","author":"BALANCE Investigators","year":"2025","unstructured":"BALANCE Investigators. Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. N Engl J Med. 2025;392(11):1065\u201378. https:\/\/doi.org\/10.1056\/NEJMoa2404991.","journal-title":"N Engl J Med"},{"issue":"4","key":"4103_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41579-024-01105-2","volume":"23","author":"CL Holmes","year":"2025","unstructured":"Holmes CL, Albin OR, Mobley HLT, Bachman MA. Bloodstream infections: mechanisms of pathogenesis and opportunities for intervention. Nat Rev Microbiol. 2025;23(4):210\u201324. https:\/\/doi.org\/10.1038\/s41579-024-01105-2.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4103_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10274-7","volume":"24","author":"H Zhao","year":"2024","unstructured":"Zhao H, Liu M, Wu J, Chen S, Yang H, Long J, et al. Mortality and genetic diversity of antibiotic-resistant bacteria associated with bloodstream infections: a systemic review and genomic analysis. BMC Infect Dis. 2024;24(1):1385. https:\/\/doi.org\/10.1186\/s12879-024-10274-7.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"4103_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/08971900211000686","volume":"35","author":"JM Chiasson","year":"2022","unstructured":"Chiasson JM, Smith WJ, Jodlowski TZ, Kouma MA, Cutrell JB. Impact of a rapid blood culture diagnostic panel on time to optimal antimicrobial therapy at a veterans affairs medical center. J Pharm Pract. 2022;35(5):722\u20139. https:\/\/doi.org\/10.1177\/08971900211000686.","journal-title":"J Pharm Pract"},{"issue":"4","key":"4103_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.02429-21","volume":"60","author":"M Verway","year":"2022","unstructured":"Verway M, Brown KA, Marchand-Austin A, Diong C, Lee S, Langford B, et al. Prevalence and mortality associated with bloodstream organisms: a population-wide retrospective cohort study. LEDEBOER N A. J Clin Microbiol. 2022;60(4):e02429-21. https:\/\/doi.org\/10.1128\/jcm.02429-21.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"4103_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-025-03020-9","volume":"25","author":"X Hu","year":"2025","unstructured":"Hu X, Zhi S, Li Y, Cheng Y, Fan H, Li H, et al. Development and application of an early prediction model for risk of bloodstream infection based on real-world study. BMC Med Inform Decis Mak. 2025;25(1):186. https:\/\/doi.org\/10.1186\/s12911-025-03020-9.","journal-title":"BMC Med Inform Decis Mak"},{"key":"4103_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.thromres.2018.04.007","volume":"166","author":"Y Wang","year":"2018","unstructured":"Wang Y, Ouyang Y, Liu B, Ma X, Ding R. Platelet activation and antiplatelet therapy in sepsis: a narrative review. Thromb Res. 2018;166:28\u201336. https:\/\/doi.org\/10.1016\/j.thromres.2018.04.007.","journal-title":"Thromb Res"},{"issue":"13","key":"4103_CR8","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1096\/fj.01-0199com","volume":"15","author":"K Singbartl","year":"2001","unstructured":"Singbartl K, Forlow SB, Ley K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J. 2001;15(13):2337\u201344. https:\/\/doi.org\/10.1096\/fj.01-0199com.","journal-title":"FASEB J"},{"issue":"12","key":"4103_CR9","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1172\/JCI29499","volume":"116","author":"A Zarbock","year":"2006","unstructured":"Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116(12):3211\u20139. https:\/\/doi.org\/10.1172\/JCI29499.","journal-title":"J Clin Invest"},{"issue":"3","key":"4103_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1160\/TH15-03-0191","volume":"114","author":"T Hohlfeld","year":"2015","unstructured":"Hohlfeld T, Schr\u00f6r K. Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions? Thromb Haemost. 2015;114(3):469\u201377. https:\/\/doi.org\/10.1160\/TH15-03-0191.","journal-title":"Thromb Haemost"},{"issue":"2","key":"4103_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jth.12472","volume":"12","author":"V Capra","year":"2014","unstructured":"Capra V, B\u00e4ck M, Angiolillo DJ, Cattaneo M, Sakariassen KS. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost. 2014;12(2):126\u201337. https:\/\/doi.org\/10.1111\/jth.12472.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"4103_CR12","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/17512433.2022.2121702","volume":"15","author":"G Gelbenegger","year":"2022","unstructured":"Gelbenegger G, Jilma B. Clinical pharmacology of antiplatelet drugs. Expert Rev Clin Pharmacol. 2022;15(10):1177\u201397. https:\/\/doi.org\/10.1080\/17512433.2022.2121702.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"4103_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12879-024-09421-x","volume":"24","author":"S Jiang","year":"2024","unstructured":"Jiang S, Xu J, Ke C, Huang P. Impact of P2Y12 inhibitors on clinical outcomes in sepsis-3 patients receiving aspirin: a propensity score matched analysis. BMC Infect Dis. 2024;24(1):575. https:\/\/doi.org\/10.1186\/s12879-024-09421-x.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"4103_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1160\/TH14-12-1067","volume":"114","author":"M Thomas","year":"2015","unstructured":"Thomas M, Storey R. The role of platelets in inflammation. Thromb Haemost. 2015;114(3):449\u201358. https:\/\/doi.org\/10.1160\/TH14-12-1067.","journal-title":"Thromb Haemost"},{"issue":"4","key":"4103_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/CCM.0000000000001554","volume":"44","author":"M Osthoff","year":"2016","unstructured":"Osthoff M, Sidler JA, Lakatos B, Frei R, Dangel M, Weisser M, et al. Low-dose acetylsalicylic acid treatment and impact on short-term mortality in staphylococcus aureus bloodstream infection: a propensity score\u2013matched cohort study. Crit Care Med. 2016;44(4):773\u201381. https:\/\/doi.org\/10.1097\/CCM.0000000000001554.","journal-title":"Crit Care Med"},{"issue":"1","key":"4103_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8\u201335. https:\/\/doi.org\/10.1159\/000521288.","journal-title":"Psychother Psychosom"},{"issue":"11","key":"4103_CR17","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1111\/jth.15048","volume":"18","author":"L Franco","year":"2020","unstructured":"Franco L, Becattini C, Beyer-Westendorf J, Vanni S, Nitti C, Re R, et al. Definition of major bleeding: prognostic classification. J Thromb Haemost. 2020;18(11):2852\u201360. https:\/\/doi.org\/10.1111\/jth.15048.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"4103_CR18","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.jtha.2024.03.005","volume":"22","author":"RI Baker","year":"2024","unstructured":"Baker RI, Choi P, Curry N, Gebhart J, Gomez K, Henskens Y, et al. Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH. J Thromb Haemost. 2024;22(7):2059\u201370. https:\/\/doi.org\/10.1016\/j.jtha.2024.03.005.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"4103_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jama.2016.0289","volume":"315","author":"M Shankar-Hari","year":"2016","unstructured":"Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):775\u201387. https:\/\/doi.org\/10.1001\/jama.2016.0289.","journal-title":"JAMA"},{"issue":"3","key":"4103_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000516647","volume":"146","author":"AS Levey","year":"2022","unstructured":"Levey AS. Defining AKD: the spectrum of AKI, AKD, and CKD. Nephron. 2022;146(3):302\u20135. https:\/\/doi.org\/10.1159\/000516647.","journal-title":"Nephron"},{"issue":"4","key":"4103_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106743","volume":"61","author":"CA Gentry","year":"2023","unstructured":"Gentry CA, Williams RJ, Whitman CM, Thind SK, Kliewer BS. Staphylococcus aureus bacteraemia treatment outcomes in patients receiving ticagrelor vs a propensity-matched cohort receiving clopidogrel. Int J Antimicrob Agents. 2023;61(4):106743. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106743.","journal-title":"Int J Antimicrob Agents"},{"issue":"586","key":"4103_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd6737","volume":"13","author":"J Sun","year":"2021","unstructured":"Sun J, Uchiyama S, Olson J, Morodomi Y, Cornax I, Ando N, et al. Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell\u2013Morell receptor to clear staphylococcus aureus bacteremia. Sci Transl Med. 2021;13(586):eabd6737. https:\/\/doi.org\/10.1126\/scitranslmed.abd6737.","journal-title":"Sci Transl Med"},{"issue":"4","key":"4103_CR23","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1007\/s40121-021-00539-y","volume":"10","author":"C Ye","year":"2021","unstructured":"Ye C, Wang C, Li Z, Li X, Pan J, Liu L, et al. The effect of combination therapy on mortality and adverse events in patients with staphylococcus aureus bacteraemia: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Ther. 2021;10(4):2643\u201360. https:\/\/doi.org\/10.1007\/s40121-021-00539-y.","journal-title":"Infect Dis Ther"},{"issue":"9","key":"4103_CR24","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/infdis\/jiab146","volume":"224","author":"ER Ulloa","year":"2021","unstructured":"Ulloa ER, Uchiyama S, Gillespie R, Nizet V, Sakoulas G. Ticagrelor increases platelet-mediated staphylococcus aureus killing, resulting in clearance of bacteremia. J Infect Dis. 2021;224(9):1566\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiab146.","journal-title":"J Infect Dis"},{"issue":"5","key":"4103_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1159\/000538549","volume":"149","author":"C Morelli","year":"2024","unstructured":"Morelli C, Rocca B, Gigante B. Infective endocarditis and antithrombotic therapy. Cardiology. 2024;149(5):513\u201322. https:\/\/doi.org\/10.1159\/000538549.","journal-title":"Cardiology"},{"issue":"2","key":"4103_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1469-0691.2008.02665.x","volume":"15","author":"J Pepin","year":"2009","unstructured":"Pepin J, Tremblay V, Bechard D, Rodier F, Walker C, Dufresne D, et al. Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin Microbiol Infect. 2009;15(2):193\u20139. https:\/\/doi.org\/10.1111\/j.1469-0691.2008.02665.x.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"4103_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.clinthera.2024.07.001","volume":"46","author":"H Essa","year":"2024","unstructured":"Essa H, Ding WY, Rana F, Zhao SS, Anson M, Austin P, et al. Aspirin and ticagrelor versus aspirin and clopidogrel or prasugrel and the effect on staphylococcal-associated infections: a real-world study. Clin Ther. 2024;46(9):689\u201395. https:\/\/doi.org\/10.1016\/j.clinthera.2024.07.001.","journal-title":"Clin Ther"},{"issue":"1","key":"4103_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001595","volume":"4","author":"M Falcone","year":"2015","unstructured":"Falcone M, Russo A, Cangemi R, Farcomeni A, Calvieri C, Barill\u00e0 F, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc. 2015;4(1):e001595. https:\/\/doi.org\/10.1161\/JAHA.114.001595.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"4103_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322293","volume":"20","author":"X Wang","year":"2025","unstructured":"Wang X, Zhou H. Impact of antiplatelet therapy on outcomes of sepsis: a systematic review and meta-analysis. PLoS ONE. 2025;20(4):e0322293. https:\/\/doi.org\/10.1371\/journal.pone.0322293.","journal-title":"PLoS ONE"},{"key":"4103_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jcrc.2018.12.004","volume":"50","author":"Y Ouyang","year":"2019","unstructured":"Ouyang Y, Wang Y, Liu B, Ma X, Ding R. Effects of antiplatelet therapy on the mortality rate of patients with sepsis: a meta-analysis. J Crit Care. 2019;50:162\u20138. https:\/\/doi.org\/10.1016\/j.jcrc.2018.12.004.","journal-title":"J Crit Care"},{"key":"4103_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2024.111597","volume":"99","author":"Y Dong","year":"2024","unstructured":"Dong Y, Wei S, Liu Y, Ji X, Yin X, Wu Z, et al. Aspirin is associated with improved outcomes in patients with sepsis-induced myocardial injury: an analysis of the MIMIC-IV database. J Clin Anesth. 2024;99:111597. https:\/\/doi.org\/10.1016\/j.jclinane.2024.111597.","journal-title":"J Clin Anesth"},{"issue":"3","key":"4103_CR32","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/CIRCRESAHA.117.310939","volume":"122","author":"RC Becker","year":"2018","unstructured":"Becker RC, Sexton T, Smyth SS. Translational implications of platelets as vascular first responders. Circ Res. 2018;122(3):506\u201322. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310939.","journal-title":"Circ Res"},{"key":"4103_CR33","doi-asserted-by":"publisher","first-page":"1043334","DOI":"10.3389\/fmicb.2022.1043334","volume":"13","author":"A Mariotti","year":"2022","unstructured":"Mariotti A, Ezzraimi AE, Camoin-Jau L. Effect of antiplatelet agents on Escherichia coli sepsis mechanisms: a review. Front Microbiol. 2022;13:1043334. https:\/\/doi.org\/10.3389\/fmicb.2022.1043334.","journal-title":"Front Microbiol"},{"key":"4103_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1220780","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Tao Q, Shen Y, Liu X, Yang Y, Ma N, et al. Aspirin eugenol ester ameliorates LPS-induced inflammatory responses in RAW264.7 cells and mice. Front Pharmacol. 2023;14:1220780. https:\/\/doi.org\/10.3389\/fphar.2023.1220780.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4103_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/09537100802503368","volume":"20","author":"J Winning","year":"2009","unstructured":"Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets. 2009;20(1):50\u20137. https:\/\/doi.org\/10.1080\/09537100802503368.","journal-title":"Platelets"},{"key":"4103_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.amjcard.2021.10.001","volume":"162","author":"N Jain","year":"2022","unstructured":"Jain N, Phadnis MA, Martin BC, Mehta JL. Potent antiplatelet therapy may reduce death from sepsis in patients on chronic dialysis. Am J Cardiol. 2022;162:209\u201311. https:\/\/doi.org\/10.1016\/j.amjcard.2021.10.001.","journal-title":"Am J Cardiol"},{"issue":"6","key":"4103_CR37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/SHK.0000000000001057","volume":"49","author":"F Du","year":"2018","unstructured":"Du F, Jiang P, He S, Song D, Xu F. Antiplatelet therapy for critically ill patients: a pairwise and Bayesian network meta-analysis. Shock. 2018;49(6):616\u201324. https:\/\/doi.org\/10.1097\/SHK.0000000000001057.","journal-title":"Shock"},{"issue":"12","key":"4103_CR38","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","volume":"35","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Outteridge SN, Ajjan RA, Phoenix F, Sangha GK, Faulkner RE, et al. Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model. Arterioscler Thromb Vasc Biol. 2015;35(12):2562\u201370. https:\/\/doi.org\/10.1161\/ATVBAHA.115.306528.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"4103_CR39","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/CCM.0000000000002654","volume":"45","author":"J Trauer","year":"2017","unstructured":"Trauer J, Muhi S, McBryde ES, Al Harbi SA, Arabi YM, Boyle AJ, et al. Quantifying the effects of prior acetyl-salicylic acid on sepsis-related deaths: an individual patient data meta-analysis using propensity matching. Crit Care Med. 2017;45(11):1871\u20139. https:\/\/doi.org\/10.1097\/CCM.0000000000002654.","journal-title":"Crit Care Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-04103-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04103-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04103-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:33:10Z","timestamp":1775568790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-04103-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4103"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-04103-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adheres to the Declaration of Helsinki.The ethical committee of the Xuanwu Hospital of Capital Medical University approved this trial in Oct 2020 (approval number: LYS[2020]103). Written and oral informed consent was obtained from all participants to publish the results of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"506"}}